Sweta Girgenrath
Vice President, Head of Cardiovascular and Neuromuscular and Cardiovascular Therapeutics Entrada Therapeutics Inc.
Sweta Girgenrath, PhD is Vice President of Therapeutic Research and External Innovation Lead at Entrada Therapeutics, where she spearheads the advancement of innovative biologic and antisense oligonucleotide (AON) therapies for rare neuromuscular and cardiac diseases. With more than 20 years of experience spanning academia and industry, she has built and led multidisciplinary research teams focused on translating disease biology into therapeutic development. Prior to joining Entrada, Sweta held leadership roles at Boston University, Pfizer, and UMass Medical School, contributing extensively to muscular dystrophy and regenerative biology research. She has successfully guided multiple Duchenne muscular dystrophy programs through global regulatory filings and remains a passionate advocate for rigorous science and patient-centered drug development.
Seminars
- Exploring the use of animal models within a program’s means to ensure preclinical work that is predictive into the clinic
- Comparing the advantages and disadvantages of 2D and 3D models for long term rare disease studies in terms of dosing and translatability
- Establishing the importance of a robust preclinical data package and how to achieve this in early strategic development
